Predictive value of abbreviated olfactory tests in prodromal Parkinson disease

the PARS Investigators

doi:10.1038/s41531-023-00530-z

Predictive value of abbreviated olfactory tests in prodromal Parkinson disease

the PARS Investigators

Neurology

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

There is disagreement in the literature whether olfaction may show specific impairments in Parkinson Disease (PD) and if olfactory tests comprised of selected odors could be more specific for diagnosis. We sought to validate previously proposed subsets of the University of Pennsylvania Smell Identification Test (UPSIT) odors for predicting conversion to PD in an independent, prodromal cohort. Conversion to PD was assessed in 229 participants in the Parkinson At Risk Study who completed baseline olfactory testing with the UPSIT and up to 12 years of clinical and imaging evaluations. No commercially available or proposed subset performed better than the full 40-item UPSIT. The proposed “PD-specific” subsets also did not perform better than expected by chance. We did not find evidence for selective olfactory impairment in Parkinson disease. Shorter odor identification tests, including commercially available 10–12 item tests, may have utility for ease of use and cost, but not for superior predictive value.

Original language	English (US)
Article number	103
Journal	npj Parkinson's Disease
Volume	9
Issue number	1
DOIs	https://doi.org/10.1038/s41531-023-00530-z
State	Published - Dec 2023

Funding

The authors declare no competing interests. P.A.V. has received grant funding from the Edmond J. Safra Foundation and Michael J. Fox Foundation and has been a consultant to Abbvie. J.F.M. has received grant support from the Department of Defense. D.J. is an employee of Denali Therapeutics, Inc. A.S. has been a consultant to the following companies: Biogen, Prilenia Therapeutics, Wave, Praxis Therapeutics, Alector, Merck and Prevail. He has received grant funding from the Michael J. Fox Foundation and NINDS. K.M. has been a consultant for Invicro, Sanofi, Biohaven, Takeda, Alkahest, Denali, Astellas, Bial, Pfizer, GE Healthcare, Lilly, Calico, Biomx, Neuramedy, Roche and the Michael J Fox Foundation. Support for this study is provided by the Department of Defense award number W81XWH-06-067. The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government.

ASJC Scopus subject areas

Neurology
Clinical Neurology
Cellular and Molecular Neuroscience

Access to Document

10.1038/s41531-023-00530-z

Cite this

@article{89307ec61a2046559e9ad4ae2bda250e,

title = "Predictive value of abbreviated olfactory tests in prodromal Parkinson disease",

abstract = "There is disagreement in the literature whether olfaction may show specific impairments in Parkinson Disease (PD) and if olfactory tests comprised of selected odors could be more specific for diagnosis. We sought to validate previously proposed subsets of the University of Pennsylvania Smell Identification Test (UPSIT) odors for predicting conversion to PD in an independent, prodromal cohort. Conversion to PD was assessed in 229 participants in the Parkinson At Risk Study who completed baseline olfactory testing with the UPSIT and up to 12 years of clinical and imaging evaluations. No commercially available or proposed subset performed better than the full 40-item UPSIT. The proposed “PD-specific” subsets also did not perform better than expected by chance. We did not find evidence for selective olfactory impairment in Parkinson disease. Shorter odor identification tests, including commercially available 10–12 item tests, may have utility for ease of use and cost, but not for superior predictive value.",

author = "{the PARS Investigators} and Vaswani, {Pavan A.} and Morley, {James F.} and Danna Jennings and Andrew Siderowf and Kenneth Marek and John Seibyl and Matthew Stern and David Russell and Kapil Sethi and Samuel Frank and Tanya Simuni and Robert Hauser and Bernard Ravina and Irene Richards and Grace Liang and Charles Adler and Rachel Saunders-Pullman and Evatt, {Marian L.} and Eugene Lai and Indu Subramanian and Penelope Hogarth and Kathryn Chung",

note = "Publisher Copyright: {\textcopyright} 2023, This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.",

year = "2023",

month = dec,

doi = "10.1038/s41531-023-00530-z",

language = "English (US)",

volume = "9",

journal = "npj Parkinson's Disease",

issn = "2373-8057",

publisher = "Springer Nature",

number = "1",

}

TY - JOUR

T1 - Predictive value of abbreviated olfactory tests in prodromal Parkinson disease

AU - the PARS Investigators

AU - Vaswani, Pavan A.

AU - Morley, James F.

AU - Jennings, Danna

AU - Siderowf, Andrew

AU - Marek, Kenneth

AU - Seibyl, John

AU - Stern, Matthew

AU - Russell, David

AU - Sethi, Kapil

AU - Frank, Samuel

AU - Simuni, Tanya

AU - Hauser, Robert

AU - Ravina, Bernard

AU - Richards, Irene

AU - Liang, Grace

AU - Adler, Charles

AU - Saunders-Pullman, Rachel

AU - Evatt, Marian L.

AU - Lai, Eugene

AU - Subramanian, Indu

AU - Hogarth, Penelope

AU - Chung, Kathryn

PY - 2023/12

Y1 - 2023/12

N2 - There is disagreement in the literature whether olfaction may show specific impairments in Parkinson Disease (PD) and if olfactory tests comprised of selected odors could be more specific for diagnosis. We sought to validate previously proposed subsets of the University of Pennsylvania Smell Identification Test (UPSIT) odors for predicting conversion to PD in an independent, prodromal cohort. Conversion to PD was assessed in 229 participants in the Parkinson At Risk Study who completed baseline olfactory testing with the UPSIT and up to 12 years of clinical and imaging evaluations. No commercially available or proposed subset performed better than the full 40-item UPSIT. The proposed “PD-specific” subsets also did not perform better than expected by chance. We did not find evidence for selective olfactory impairment in Parkinson disease. Shorter odor identification tests, including commercially available 10–12 item tests, may have utility for ease of use and cost, but not for superior predictive value.

AB - There is disagreement in the literature whether olfaction may show specific impairments in Parkinson Disease (PD) and if olfactory tests comprised of selected odors could be more specific for diagnosis. We sought to validate previously proposed subsets of the University of Pennsylvania Smell Identification Test (UPSIT) odors for predicting conversion to PD in an independent, prodromal cohort. Conversion to PD was assessed in 229 participants in the Parkinson At Risk Study who completed baseline olfactory testing with the UPSIT and up to 12 years of clinical and imaging evaluations. No commercially available or proposed subset performed better than the full 40-item UPSIT. The proposed “PD-specific” subsets also did not perform better than expected by chance. We did not find evidence for selective olfactory impairment in Parkinson disease. Shorter odor identification tests, including commercially available 10–12 item tests, may have utility for ease of use and cost, but not for superior predictive value.

UR - http://www.scopus.com/inward/record.url?scp=85163799521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85163799521&partnerID=8YFLogxK

U2 - 10.1038/s41531-023-00530-z

DO - 10.1038/s41531-023-00530-z

M3 - Article

C2 - 37386033

AN - SCOPUS:85163799521

SN - 2373-8057

VL - 9

JO - npj Parkinson's Disease

JF - npj Parkinson's Disease

IS - 1

M1 - 103

ER -

Predictive value of abbreviated olfactory tests in prodromal Parkinson disease

Abstract

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this